Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Novo Nordisk A/S (NYSE:NVO)

46.89
Delayed Data
As of Aug 26
 +0.04 / +0.09%
Today’s Change
45.80
Today|||52-Week Range
59.00
-19.27%
Year-to-Date
Pharmaceuticals are the New Bonds
Aug 26 / GuruFocus News - Paid Partner Content
Novo Nordisk A/S Focuses on New Drugs
Aug 16 / MotleyFool.com - Paid Partner Content
Better Buy: AbbVie Inc. vs. Eli Lilly & Co.
Aug 17 / MotleyFool.com - Paid Partner Content
3 Beaten-Up Big Pharma Stocks: Are They Bargains?
Aug 14 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close46.85
Today’s open46.88
Day’s range46.62 - 47.18
Volume1,600,893
Average volume (3 months)1,832,552
Market cap$91.9B
Dividend yield0.97%
Data as of 4:02pm ET, 08/26/2016

Growth & Valuation

Earnings growth (last year)+12.05%
Earnings growth (this year)--
Earnings growth (next 5 years)+11.15%
Revenue growth (last year)+1.43%
P/E ratio3.3
Price/Sales9.38
Price/Book17.47

Competitors

 Today’s
change
Today’s
% change
AGNAllergan+1.62+0.69%
LLYEli Lilly and Co+0.23+0.29%
BMYBristol-Myers Squibb+0.01+0.02%
CELGCelgene+0.88+0.82%
Data as of 4:01pm ET, 08/26/2016

Financials

Next reporting dateOctober 28, 2016
EPS forecast (this quarter)$0.57
Annual revenue (last year)$16.0B
Annual profit (last year)$5.2B
Net profit margin32.30%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
President &
Chief Executive Officer
Lars Rebien Sørensen
Chief Financial Officer &
Executive Vice President
Jesper Brandgaard
Corporate headquarters
Bagsværd, Capital Region

Forecasts

Partner Offers

Search for Jobs